India, May 15 -- GT Biopharma Inc. (GTBP), a clinical-stage immuno-oncology company, on Friday announced first quarter results and provided updates on its developing pipeline.
The company is advancing cancer therapeutics through its proprietary Tetra-specific killer engager natural killer (TriKE NK) cell engager platform to utilize the patient's NK immune cells to fight cancer.
Q1 2026:
The company recorded a net loss of $2.83 million, or $0.11 per share in Q1 2026, while in the same period of 2025 the net loss was $0.78 million, or $0.33 per share. Losses were incurred due to higher losses from operations, amounting to $2.8 million, and interest expenses of $0.06 million.
Research and development expenses (R&D) were $0.41 million, cons...